Basit öğe kaydını göster

Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial

dc.contributor.authorGuler, Emine Nilufer
dc.contributor.authorDemir, Atakan
dc.contributor.authorMandel, Nil Molinas
dc.contributor.authorPAYDAŞ, SEMRA
dc.contributor.authorDemir, Gokhan
dc.contributor.authorER, Ozlem
dc.contributor.authorTurhal, Nazim Serdal
dc.contributor.authorBavbek, Sevil
dc.contributor.authorEralp, Yesim
dc.contributor.authorSaip, Pinar Mualla
dc.contributor.authorAydiner, Adnan
dc.contributor.authorOYAN ULUÇ, Başak
dc.contributor.authorKilickap, Sadettin
dc.contributor.authorUskent, Necdet
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorKaplan, Mehmet Ali
dc.contributor.authorYanmaz, Mustafa Teoman
dc.contributor.authorDemir, Hacer
dc.contributor.authorAlan, Ozkan
dc.contributor.authorKORKMAZ, Taner
dc.contributor.authorOlgun, Polat
dc.contributor.authorUysal, Ozlem Sonmez
dc.contributor.authorAltundag, Kadri
dc.contributor.authorGunduz, Seyda
dc.contributor.authorGunaldi, Meral
dc.contributor.authorSari, Murat
dc.contributor.authorBeypinar, Ismail
dc.contributor.authorBAŞARAN, Gül
dc.date.accessioned2021-03-03T19:42:05Z
dc.date.available2021-03-03T19:42:05Z
dc.date.issued2020
dc.identifier.citationDemir A., Mandel N. M. , PAYDAŞ S., Demir G., ER O., Turhal N. S. , Bavbek S., Eralp Y., Saip P. M. , Guler E. N. , et al., "Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial", BALKAN MEDICAL JOURNAL, cilt.37, sa.2, ss.104-107, 2020
dc.identifier.issn2146-3123
dc.identifier.otherav_55f801b5-6322-46ca-a57b-de3d667973b3
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/60714
dc.identifier.urihttps://doi.org/10.4274/balkanmedj.galenos.2020.2019.11.143
dc.description.abstractBackground: The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer. In spite of this, the activity of CDK4/6 inhibitors in patients with metastatic breast cancer who have progressed despite receiving multiple lines of treatment is not well understood.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectKlinik Tıp
dc.subjectTemel Tıp Bilimleri
dc.subjectKlinik Tıp (MED)
dc.subjectTIP, GENEL & İÇECEK
dc.subjectTıp
dc.titleEfficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
dc.typeMakale
dc.relation.journalBALKAN MEDICAL JOURNAL
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume37
dc.identifier.issue2
dc.identifier.startpage104
dc.identifier.endpage107
dc.contributor.firstauthorID2279135


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster